Overview

A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Status:
Terminated
Trial end date:
2020-04-06
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B (CHB).
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche